George Sakoulas, MD

George Sakoulas, MD, discusses how transitioning pneumonia patients from IV to oral therapy after 3 to 4 days of clinical stability supports effective 7-day treatment courses, while patients who are immunocompromised and those with Pseudomonas infections require individualized, extended management.

George Sakoulas, MD, discusses how updated guidelines recommend shorter antibiotic courses (5 to 7 days) for patients with pneumonia, emphasizing that early aggressive treatment within the first 72 hours is crucial for reducing hospital stays and improving patient outcomes.

George Sakoulas, MD, discusses how ceftaroline serves as an effective stewardship-aligned option for community-acquired pneumonia involving gram-positive organisms, particularly in older and high-risk patients, while noting its limitations in gram-negative and health care–associated infections.

George Sakoulas, MD, discusses how antimicrobial selection for patients with pneumonia depends on illness severity, seasonal pathogen patterns, comorbidities, and prior antibiotic exposure, with particular attention to high-risk populations requiring tailored therapy.

George Sakoulas, MD, discusses how COVID-19 has disrupted traditional respiratory virus patterns with summer surges now preceding the typical winter influenza season, while declining vaccine uptake among younger populations threatens to leave vulnerable groups increasingly exposed to seasonal illness complications.

Sakoulas offered his insights for when he considers discharging patients and strategies to avoid readmission.

In this conversation, Sakoulas discusses a specific therapy indicated for CABP.

George Sakoulas, MD, offered clinical considerations for treatment selection.

George Sakoulas, MD, provided commentary on challenging patients with comorbidities such as COPD, structural lung disease, asthma, and other health issues.

George Sakoulas, MD, shares key takeaways on soft tissue infections from ID week 2023.

Dr George Sakoulas provides insight on how single-dose agents fit into antimicrobial stewardship for soft tissue infections.

George Sakoulas, MD, provides key insights on the management of soft tissue infections including the role of single-dose agents and treating patients in an outpatient setting.

An expert in infectious diseases shares treatment considerations and clinical strategies for the management of community acquired pneumonia (CAP).

George Sakoulas, MD, highlights persistent unmet needs in managing CAP and key takeways from ID week 2023.

An expert in infectious diseases comments on multidrug-resistant pathogens such as pneumococcus in CAP, and shares thoughts on balancing antimicrobial stewardship with the pharmacoeconomics of antimicrobial therapies in CAP.

An expert in infectious diseases reviews currently available therapeutic options for inpatient and outpatient treatment of ABSSSI and examines the advantages of using single-dose agents in patients.

George Sakoulas, MD, provides an overview of the burden of acute bacterial skin and skin structure infections (ABSSSI) and patient selection for treatment in the outpatient setting.

Dr George Sakoulas shares strategies for selecting single and combination therapy when dealing with empiric vs focused treatment regimens for CAP and discusses clinical considerations for elderly patients hospitalized with CAP.

George Sakoulas, MD, provides insight on the burden on the healthcare community of community acquired pneumonia (CAP) and the influence of geography and seasonal variations on CAP.

Growing evidence suggests that antimicrobials also interact with host innate immunity to provide potent indirect effects which enhance bacterial clearance and may result in more rapid and complete effects

Therapy options have increased in recent decades, yet there is a lack of guidance.